Clinical Trial Update: Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating dual mTORC1/mTORC2 inhibitor with anastrozole for hormone receptor–positive endometrial carcinoma (metastatic). Status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma
• Endometrial Carcinoma

Drugs mentioned

• Anastrozole (Anastrozole)
• Dual mTORC1/mTORC2 inhibitor

Snippet

Sponsor: Centre Leon Berard | Conditions: Endometrial Carcinoma, Metastatic Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN